Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.61 |
| ▸ | CES1 | P23141 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8292394 | 0.88 | CES2 (0.61) | CES2CES1ALDH1A1MAPK14L3MBTL1 | |
| SCHEMBL2562024 | 0.86 | CES2 (0.64) | CES2CES1ALDH1A1MAPK14L3MBTL1 | |
| SCHEMBL30485086 | 0.86 | CES2 (0.64) | CES2CES1ALDH1A1MAPK14L3MBTL1 | |
| SCHEMBL7804388 | 0.86 | CES2 (0.59) | CES2CES1ALDH1A1MAPK14L3MBTL1 | |
| SCHEMBL940243 | 0.86 | CES2 (0.64) | CES2CES1ALDH1A1MAPK14L3MBTL1 | |
| SCHEMBL9046982 | 0.86 | CES2 (0.64) | CES2CES1ALDH1A1MAPK14L3MBTL1 | |
| SCHEMBL6518724 | 0.85 | CES2 (0.57) | CES2CES1ALDH1A1MAPK14L3MBTL1 | |
| SCHEMBL9522760 | 0.85 | CES2 (0.57) | CES2CES1ALDH1A1MAPK14L3MBTL1 | |
| SCHEMBL6939794 | 0.85 | CES2 (0.57) | CES2CES1ALDH1A1MAPK14L3MBTL1 | |
| SCHEMBL12909549 | 0.84 | CES2 (0.61) | CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5159089-A | Using a sulfur methylide compound | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-10-27 | — | — | US | claimed |
| WO-2020210630-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 THERAPEUTICS, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| US-9732029-B2 | Nitroso compounds as nitroxyl donors and methods of use thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9725402-B2 | Nitroso compounds as nitroxyl donors and methods of use thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9249145-B2 | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140336137-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | CARDIOXYL PHARMACEUTICALS, INC. | 2014-11-13 | — | — | US | disclosed |
| US-8791134-B2 | Nitroso compounds as nitroxyl donors and methods of use thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130045951-A1 | Novel Nitroso Compounds as Nitroxyl Donors and Methods of Use Thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2013-02-21 | — | — | US | disclosed |
| US-8318705-B2 | Nitroso compounds as nitroxyl donors and methods of use thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| WO-2009137717-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | CARDIOXYL PHARMACEUTICALS INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090281062-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | EVOTEC LTD. (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20080200465-A1 | Substituted with a morpholine group through amido heterocylic groups; interfering with the expression of genes essential for the pathogen's proliferation; treating viral and protozoan infections in mammals | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-7348427-B2 | Antipathogenic benzamide compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20080051353-A1 | Avermectin And Avermectin Monosaccharide Substituted In The 4\"- And 4\" Position Respectively | SYNGENTA CROP PROTECTION, INC. (US) | 2008-02-28 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-5312815-A | Fungicidal (+)-2-(2,4-difluorophenyl)-3-methyl-1-(1H-1,2,4-triazol-1-yl)3-(6-(1H-1,2,4-triazol-1-yl)pyridazin-3-ylthio) butan-2-ol | ROUSSEL MORISHITA CO., LTD. (JP) | 1994-05-17 | — | — | US | disclosed |
| EP-0552974-A1 | A 1-aryl-2-(1H-1,2-4-triazol-1-yl) ethanol derivative and antifungal compositions containing that derivative | ROUSSEL MORISHITA Co., Ltd. (JP) | 1993-07-28 | — | — | EP | disclosed |
| US-5159089-A | Using a sulfur methylide compound | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-10-27 | — | — | US | disclosed |
| EP-0415320-A2 | Selective production of threo-epoxy compounds | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1991-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200465-A1 | Substituted with a morpholine group through amido heterocylic groups; interfering with the expression of genes essential for the pathogen's proliferation; treating viral and protozoan infections in mammals | IRF3, BCL3, L3MBTL3 | CES2 2136/4885CES1 3325/4885ALDH1A1 3117/4885 |
| US-20140336137-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | NOXO1, TNNI3, HAO2 | CES2 3013/4885CES1 1515/4885ALDH1A1 624/4885 |
| US-20090281062-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | NOXO1, TNNI3, HAO2 | CES2 3013/4885CES1 1515/4885ALDH1A1 624/4885 |
| US-20130045951-A1 | Novel Nitroso Compounds as Nitroxyl Donors and Methods of Use Thereof | NOXO1, TNNI3, HAO2 | CES2 3013/4885CES1 1515/4885ALDH1A1 624/4885 |
| US-20080051353-A1 | Avermectin And Avermectin Monosaccharide Substituted In The 4\"- And 4\" Position Respectively | CCR6, CHRM4, CHRM5 | CES2 384/4885CES1 487/4885ALDH1A1 3420/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | CES2 4820/4885CES1 3698/4885ALDH1A1 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.